Jul 2 |
Checkpoint resubmits FDA application for cosibelimab
|
Jul 2 |
Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering
|
Jul 2 |
Checkpoint Therapeutics looks to raise $12M through direct offering
|
Jul 2 |
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Jul 2 |
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
|
Jun 24 |
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|
May 13 |
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
May 12 |
Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)
|
May 10 |
Checkpoint Therapeutics GAAP EPS of -$0.33
|
May 10 |
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
|